Skip to content

Repligen Corp

RGEN· NasdaqCore metricsCIK 730272

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -3.49%
Market cap
$10.65B
63.92M shares
Filings
1,040
$209.31M
Q3 2026+16.4% FY25 yoy
-$38.43M
Q3 2026N/M FY25 yoy
-$29.55M
Q3 2026N/M FY25 yoy
$89.17M
Q3 2026derived−37.3% FY25 yoy
-$0.68
Q3 2026N/M FY25 yoy
$726.96M
Q3 2026−25.3% FY25 yoy
$10.65B
—
13.2×
5.1×
1.00%
—

Twelve months to Sep 30, 2026 · derived

Price

$166.66+8.62%+$13.22past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$738.26MFY 2025
$801.54M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$738,256,000reported
FY 20242024-12-31$634,439,000reported
FY 20232023-12-31$632,362,000 revisedreported
FY 20222022-12-31$801,536,000 revisedreported
FY 20212021-12-31$670,534,000reported
FY 20202020-12-31$366,260,000reported
FY 20192019-12-31$270,245,000reported
FY 20182018-12-31$194,032,000reported
FY 20172017-12-31$141,236,000reported
FY 20162016-12-31$104,541,000reported
FY 20152015-12-31$83,537,000reported
FY 20142014-12-31$63,548,000reported

Capital returns

Dividends and buybacks · FY2021 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$0.00$0.00—56.33M sh+0.3%0.0%
FY2024—$0.00$0.00—56.15M sh+0.7%0.0%
FY2023—$14.39M$14.39M—55.77M sh+0.4%18.5%
FY2022—$0.00$0.00—55.56M sh+0.4%0.0%
FY2021—$0.00$0.00—55.33M sh+1.0%0.0%

Segments

Assets by Geography, FY2019 to FY2025FY2019North America · FY2019 · $1.26BEurope · FY2019 · $133.60MAPAC · FY2019 · $6.30MFY2020North America · FY2020 · $1.70BEurope · FY2020 · $188.70MAPAC · FY2020 · $17.04MFY2021North America · FY2021 · $2.08BEurope · FY2021 · $243.08MAPAC · FY2021 · $32.56MFY2022North America · FY2022 · $2.21BEurope · FY2022 · $287.54MAPAC · FY2022 · $27.87MFY2023North America · FY2023 · $2.38BEurope · FY2023 · $426.15MAPAC · FY2023 · $27.17MFY2024North America · FY2024 · $2.31BEurope · FY2024 · $410.28MAPAC · FY2024 · $113.84MFY2025North America · FY2025 · $2.34BEurope · FY2025 · $489.93MAPAC · FY2025 · $119.59M
LineFY2025ShareChange
North America$2.34B79%+1.5%
Europe$489.93M17%+19.4%
APAC$119.59M4.1%+5.1%
Total$2.95B

From the 10-K filed Feb 26, 2026RGEN

Biological products, except diagnostic substances

Repligen Corp is the 12th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Repligen Corp · CIK 730272 · Engraved from SEC EDGAR